Bofanglutide Reduces HbA1c in Type 2 Diabetes

A recent study published online on June 30 in the *Annals of Internal Medicine* reports that bofanglutide, a glucagon‑like peptide‑1 (GLP‑1) receptor agonist, produces more meaningful reductions in hemoglobin A1c (HbA1c) levels than semaglutide in adults with type 2 diabetes mellitus (T2DM). The research compared the glycaemic effects of the two drugs in a cohort of patients with established T2DM, measuring changes in HbA1c as the primary endpoint.

The investigators found that patients treated with bofanglutide achieved a greater average drop in HbA1c compared with those receiving semaglutide, indicating superior glycaemic control. Both medications belong to the same class of GLP‑1 receptor agonists, yet the data suggest that bofanglutide may offer a clinically relevant advantage for patients seeking tighter blood‑glucose management. The study adds to the growing evidence base guiding clinicians in selecting optimal pharmacotherapy for T2DM.

These findings may influence treatment decisions for adults with T2DM, as clinicians weigh the relative efficacy of GLP‑1 receptor agonists. The demonstrated superiority of bofanglutide in reducing HbA1c could position it as a preferred option for patients requiring more pronounced glycaemic improvement.